Mental Health Technology Patents

Mental health technology patents span digital therapeutics; mental health apps; neurostimulation; and AI-based screening — with major activity from medical device companies; pharmaceutical companies; and digital health startups: MAJOR MENTAL HEALTH TECHNOLOGY PATENT HOLDERS: PEAR THERAPEUTICS (DISCONTINUED 2023; IP ACQUIRED): 50+ patents; specific prescription digital therapeutic (PDT) for substance use disorder (reSET) and opioid use disorder (reSET-O) — specific interactive CBT module delivery algorithm; specific FDA-cleared prescription digital therapeutic architecture (specific clinician-prescribed app; specific patient engagement tracking; specific FDA 510(k) cleared software); HEADSPACE HEALTH (HEADSPACE + GINGER MERGER): 100+ patents; specific mindfulness meditation guidance algorithm; specific workplace behavioral health platform; WOEBOT HEALTH: 50+ patents; specific conversational AI therapy chatbot (specific CBT-based dialogue management; specific Woebot rule-based + ML hybrid dialogue; specific mood tracking session); CALM: 50+ patents; specific sleep story audio content + specific sleep tracking integration; BEACON BIOSIGNALS (ACQUIRED BY MAYO CLINIC): specific EEG-based sleep staging algorithm (specific ambulatory EEG + specific deep learning sleep stage classifier); NEURALINK: 200+ patents; specific implantable brain-computer interface (specific ultra-flexible electrode thread + specific insertion robot for specific neuron-adjacent placement; specific N1 chip for specific spike sorting + wireless transmission; specific hermetic titanium enclosure); NEUROSTIMULATION: MAGSTIM; NEUROSTAR; BRAINSWAY; NEXSTIM: specific transcranial magnetic stimulation (TMS) coil design (specific figure-8 coil geometry for specific depth + focality trade-off; specific H-coil deep TMS for specific prefrontal + limbic circuit stimulation); specific FDA-cleared TMS protocol (specific pulse sequence + specific inter-pulse interval + specific session duration for specific treatment-resistant depression); NEUROSIGMA: specific transcutaneous (non-invasive) vagus nerve stimulation (tVNS) for specific anxiety + depression; ELECTROCORE: specific non-invasive vagus nerve stimulation nVNS.

AI-based mental health screening; passive sensing from smartphones and wearables; and biomarker detection represent some of the most active and contested patent areas in mental health technology — where machine learning applied to behavioral and physiological data creates novel innovations: AI MENTAL HEALTH SCREENING PATENT LANDSCAPE: VOCAL BIOMARKER PATENTS: MINDSTRONG (ACQUIRED); SONDE HEALTH; WINTERLIGHT LABS; COGITO: specific depression + anxiety detection from voice (specific acoustic feature extraction: jitter; shimmer; speaking rate; pitch variability; pause duration → specific ML classifier for specific PHQ-9 correlated depression score); specific voice-based cognitive impairment screening (specific spontaneous speech analysis for specific Alzheimer + MCI biomarker); SPECIFIC PATENTABLE VOCAL BIOMARKER INNOVATIONS: specific specific vocal feature set + specific model architecture + specific clinical validation against specific gold-standard measure (specific PHQ-9 correlation coefficient or AUC must be measured + reported in specification); SMARTPHONE PASSIVE SENSING: MINDSTRONG; MIT CLINICAL MACHINE LEARNING GROUP; MINDSTRONGHEALTH: specific digital phenotyping (specific smartphone usage pattern: screen time + app usage + typing dynamics + accelerometer + GPS mobility → specific ML model for specific depression severity proxy); SPECIFIC PATENTABLE PASSIVE SENSING INNOVATIONS: specific feature extraction from specific passive phone signal type + specific clinical correlation algorithm + specific specific sensitivity/specificity measurement; WEARABLE MENTAL HEALTH PATENTS: WHOOP; OURA; GARMIN; APPLE WATCH: specific HRV-based stress detection (specific SDNN or RMSSD from PPG signal + specific ML stress index for specific alerting threshold); specific sleep quality algorithm (specific multi-sensor: accelerometer + PPG + skin temperature + SpO2 + EDA → specific sleep architecture staging + specific mental health correlation model); EMPATICA: specific EDA (electrodermal activity) wrist-worn sensor; specific stress episode detection algorithm (specific tonic + phasic EDA decomposition for specific arousal event detection); SPECIFIC PATENTABLE WEARABLE INNOVATIONS: specific specific sensor combination + specific signal processing algorithm + specific clinical validation correlation with specific validated scale (PHQ-9; GAD-7; PSS; PSQI) with specific AUC; NLP MENTAL HEALTH PATENTS: MICROSOFT (LINKEDIN DATA); ORACLE HEALTH: specific depression risk detection from text (specific linguistic feature: first-person pronoun frequency + negative affect words + specific LM perplexity → specific risk flag for specific care team alert).

FDA Software as a Medical Device (SaMD) regulation is the most critical regulatory consideration for mental health technology IP — directly affecting patentability; claim drafting; and product development: FDA SaMD MENTAL HEALTH TECHNOLOGY OVERVIEW: WHAT REQUIRES FDA CLEARANCE FOR MENTAL HEALTH APPS: PRESCRIPTION DIGITAL THERAPEUTICS (PDTs): any software that provides a treatment intervention for a diagnosed psychiatric condition (depression; anxiety; PTSD; OUD; SUD; schizophrenia) = Class II medical device requiring 510(k) clearance or De Novo; FDA-CLEARED MENTAL HEALTH APPS (as of 2025): Pear reSET (SUD CBT; FDA-cleared 2017; first FDA-cleared PDT; company bankrupt 2023); Pear reSET-O (OUD CBT; FDA-cleared 2018); Freespira (PTSD + panic disorder biofeedback; FDA-cleared); Rejoyn (adjunctive depression treatment; FDA-cleared 2023 — first FDA-cleared prescription app for MDD); WHAT DOES NOT REQUIRE FDA CLEARANCE (FDA Digital Health Policy): general wellness apps (Calm; Headspace general mindfulness); apps for healthy lifestyle decisions without disease treatment intent; CLINICAL DECISION SUPPORT (CDS): provider-facing CDS that displays information but requires clinician interpretation = lower risk; IMPACT ON IP STRATEGY: FDA CLEARANCE AS MOAT: once FDA-cleared; 510(k) clearance creates regulatory barrier to entry; competitor must also obtain clearance for substantially equivalent product; specific clinical validation data (sensitivity/specificity/AUC) from FDA submission creates patentable innovation anchoring claims in specific measured performance; CLAIM DRAFTING STRATEGY: claims should reference specific clinical validation measurement outcomes to avoid § 101 abstract idea rejection (specific ML algorithm + specific clinical outcome = eligible); PROVISIONAL TIMING: file provisional patent BEFORE FDA Pre-Sub meeting to preserve priority date on any innovations disclosed in FDA submission; FDA BREAKTHROUGH DEVICE DESIGNATION: specific novel mental health device may qualify for Breakthrough Device designation = expedited FDA review + enhanced pre-submission interaction; HIPAA AND PRIVACY CONSIDERATIONS: any mental health app collecting PHI = HIPAA-regulated; COPPA if under-13 users; state mental health parity laws; clinical validation data is both trade secret + patent claim anchor.

Mental health technology startups operate in an area with unique ethical; regulatory; and IP considerations — where FDA clearance; clinical validation; and data privacy intersect with patent strategy: MENTAL HEALTH TECHNOLOGY STARTUP IP STRATEGY: WHAT IS PATENTABLE IN MENTAL HEALTH TECHNOLOGY: THERAPEUTIC CONTENT DELIVERY: specific novel CBT; DBT; or ACT module delivery algorithm (specific adaptive session sequencing + specific patient engagement model + specific clinical outcome prediction); specific novel exposure therapy VR protocol (specific virtual environment parameters + specific physiological response integration for specific anxiety disorder protocol); CLINICAL DECISION SUPPORT: specific novel risk stratification algorithm (specific multi-signal input + specific ML model + specific specific AUC on specific clinical validation cohort for specific suicide risk or crisis prediction); DIGITAL BIOMARKER: specific novel passive signal + specific novel algorithm + specific measured clinical correlation; NEUROSTIMULATION: specific novel stimulation parameter set (waveform; frequency; duration; site) with specific measured clinical effect; § 101 IN MENTAL HEALTH TECHNOLOGY: WHAT FAILS: pure mental steps (cognitive behavioral therapy method); laws of nature (correlation between symptom and diagnosis); diagnostic method without novel technology; WHAT MIGHT SURVIVE: specific algorithm + specific hardware sensor + specific measured clinical validation (AUC; sensitivity/specificity; PHQ-9 correlation); specific signal processing algorithm with measured improvement in sensitivity; TRADE SECRETS IN MENTAL HEALTH TECHNOLOGY: trained depression screening ML model weights; clinical validation dataset from proprietary real-world evidence; specific NLP feature weights for text-based screening; specific CBT module engagement optimization parameters; SPECIFIC ETHICAL + REGULATORY CONSIDERATIONS: algorithmic bias in mental health screening (FDA requires bias testing across demographic subgroups; patents should reference bias-mitigated validation); data sensitivity (mental health data is most sensitive category; HIPAA + state mental health record laws; Illinois PIPA; EU GDPR Article 9 special categories); duty to warn exceptions to clinical confidentiality; ACQUISITION LANDSCAPE: Headspace + Ginger (2021); Spring Health; Modern Health; SonderMind all raised significant capital; Teladoc (BetterHelp); CVS (Lyra Health-adjacent); KEY FTO CONSIDERATIONS: Pear Therapeutics IP (bankruptcy asset acquisition); NeuroStar TMS neurostimulation; Neuralink BCI (early stage); Microsoft + Oracle depression detection from behavioral data; Empatica EDA stress wearable.